RIO DE JANEIRO, BRAZIL - Dostarlimab, an experimental drug that could eliminate cancer in 100% of the cases in an American study, should be available in Brazil in August this year, according to the pharmaceutical company GSK Brasil. The drug already has approval from Anvisa.
The monoclonal antibody was used intravenously in the test to treat colorectal tumors. Within six months of taking the drug, the patients' Subscribe to our Premium Membership Plan. Already Subscribed? Login Here